Dicerna Pharmaceuticals Overview
- Year Founded
-
2007
- Status
-
Acquired/Merged
- Employees
-
302
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$3.3B
Dicerna Pharmaceuticals General Information
Description
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, cardiovascular diseases, cancers, and other liver problems. The company uses its ribonucleic acid interference technology platform to develop its products. In addition, Dicerna's proprietary GalXC technology focuses on silencing disease-causing genes. The product candidates are nedosiran (for primary hyperoxaluria), belcesiran (for genetic liver disease), DCR-PCSK9 (for cardiovascular disease), and RG6346 (for hepatitis B virus) among others. Dicerna generates revenue by forming collaborative relationships with pharmaceutical companies such as Eli Lilly, Roche, Novo Nordisk, and others.
Contact Information
Website
www.dicerna.com(Operating Subsidiary)
Corporate Office
- 75 Hayden Avenue
- Lexington, MA 02421
- United States
Corporate Office
- 75 Hayden Avenue
- Lexington, MA 02421
- United States
Dicerna Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 18. Merger/Acquisition | 28-Dec-2021 | $3.3B | Completed | Generating Revenue | ||
| 17. Secondary Transaction - Private | 12-Feb-2019 | Completed | Generating Revenue | |||
| 16. PIPE | 29-Oct-2018 | Completed | Generating Revenue | |||
| 15. PIPE | 24-Oct-2018 | Completed | Generating Revenue | |||
| 14. Grant | 20-Sep-2018 | Completed | Generating Revenue | |||
| 13. 2PO | 10-Sep-2018 | Completed | Generating Revenue | |||
| 12. Secondary Transaction - Open Market | 31-Mar-2018 | Completed | Generating Revenue | |||
| 11. PIPE | 11-Apr-2017 | Completed | Generating Revenue | |||
| 10. Secondary Transaction - Open Market | 31-Mar-2016 | $202M | Completed | Clinical Trials - Phase 1 | ||
| 9. Secondary Transaction - Open Market | 11-Mar-2015 | $202M | Completed | Clinical Trials - Phase 1 |
Dicerna Pharmaceuticals Comparisons
Industry
Financing
Details
Dicerna Pharmaceuticals Competitors (62)
One of Dicerna Pharmaceuticals’s 62 competitors is Alnylam Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Regulus Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Gilead Sciences | Formerly VC-backed | Foster City, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Merck & Co. | Corporation | Rahway, NJ |
Dicerna Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Dicerna Pharmaceuticals Patents
Dicerna Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2024002985-A | Compositions and methods for inhibiting transmembrane serine protease 6 (tmprss6) expression | Active | 24-Jun-2022 | ||
| AU-2023288906-A1 | Compositions and methods for inhibiting transmembrane serine protease 6 (tmprss6) expression | Pending | 24-Jun-2022 | ||
| JP-7560616-B2 | Compositions and methods for inhibiting transmembrane serine protease 6 (tmprss6) expression | Active | 24-Jun-2022 | ||
| US-20230416743-A1 | Compositions and methods for inhibiting snca expression | Pending | 13-May-2022 | ||
| AU-2023267664-A1 | Compositions and methods for inhibiting snca expression | Pending | 13-May-2022 | C12N15/113 |
Dicerna Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Dicerna Pharmaceuticals Former Investors (22)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 4BIO Capital | Venture Capital | Minority | ||
| Abingworth | Venture Capital | Minority | ||
| Alexion | Corporation | Minority | ||
| Aquilo Capital Management | Hedge Fund | Minority | ||
| Bain Capital Life Sciences | Corporate Venture Capital | Minority |
Dicerna Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
23.59 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,784
Rank
Percentile
Pharmaceuticals
Industry
of 955
Rank
Percentile
Biotechnology
Subindustry
of 440
Rank
Percentile
Dicerna Pharmaceuticals FAQs
-
When was Dicerna Pharmaceuticals founded?
Dicerna Pharmaceuticals was founded in 2007.
-
Where is Dicerna Pharmaceuticals headquartered?
Dicerna Pharmaceuticals is headquartered in Lexington, MA.
-
What is the size of Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals has 302 total employees.
-
What industry is Dicerna Pharmaceuticals in?
Dicerna Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Dicerna Pharmaceuticals a private or public company?
Dicerna Pharmaceuticals is a Private company.
-
What is the current valuation of Dicerna Pharmaceuticals?
The current valuation of Dicerna Pharmaceuticals is .
-
What is Dicerna Pharmaceuticals’s current revenue?
The current revenue for Dicerna Pharmaceuticals is .
-
How much funding has Dicerna Pharmaceuticals raised over time?
Dicerna Pharmaceuticals has raised $387M.
-
Who are Dicerna Pharmaceuticals’s investors?
4BIO Capital, Abingworth, Alexion, Aquilo Capital Management, and Bain Capital Life Sciences are 5 of 22 investors who have invested in Dicerna Pharmaceuticals.
-
Who are Dicerna Pharmaceuticals’s competitors?
Alnylam Pharmaceuticals, Regulus Therapeutics, Gilead Sciences, Adaptimmune Therapeutics, and Merck & Co. are some of the 62 competitors of Dicerna Pharmaceuticals.
-
When was Dicerna Pharmaceuticals acquired?
Dicerna Pharmaceuticals was acquired on 28-Dec-2021.
-
Who acquired Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals was acquired by Novo Nordisk.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
